Personalising Systemic Therapy Across the Disease Spectrum

The treatment landscape for UC, including muscle-invasive bladder cancer (MIBC), is rapidly advancing with new combination regimens, updated guidelines (e.g., ESMO), and a focus on multidisciplinary, personalised care. Immunotherapy-based combinations are now key in first-line treatment for advanced UC, aiming to improve survival and quality of life.

For MIBC, perioperative systemic therapies (neoadjuvant/adjuvant) are reshaping care by reducing recurrence and enhancing outcomes. Success depends on coordinated care among urologists, oncologists, and allied health professionals.

Managing adverse events (AEs) is crucial. Early recognition and proactive patient education help maintain treatment adherence and improve satisfaction.

This educational module supports best-practice adoption and informed, holistic UC care.